Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease

[Image: see text] GLP-1 agonists have become increasingly interesting as a new Parkinson’s disease (PD) clinical treatment strategy. Additional preclinical studies are important to validate this approach and define the disease stage when they are most effective. We hence characterized the efficacy o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ACS Pharmacol Transl Sci
Hlavní autoři: Wang, Vicki, Kuo, Tung-Tai, Huang, Eagle Yi-Kung, Ma, Kuo-Hsing, Chou, Yu-Ching, Fu, Zhao-Yang, Lai, Li-Wen, Jung, Jin, Choi, Hoi-II, Choi, Doo-Sup, Li, Yazhou, Olson, Lars, Greig, Nigel H., Hoffer, Barry J., Chen, Yuan-Hao
Médium: Artigo
Jazyk:Inglês
Vydáno: American Chemical Society 2021
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8033754/
https://ncbi.nlm.nih.gov/pubmed/33860208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.1c00013
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky